Cargando…
Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations
BACKGROUND: Endogenous Peptide Inhibitor of CXCR4 (EPI-X4) is a natural antagonist of the CXC chemokine receptor 4 (CXCR4). EPI-X4 is a 16-mer peptide that is released from human serum albumin (HSA) by acidic aspartic proteases such as Cathepsin D and E. Since human serum albumin (HSA) is an importa...
Autores principales: | Gilg, Andrea, Harms, Mirja, Olari, Lia-Raluca, Urbanowitz, Ann-Kathrin, Bonig, Halvard, Münch, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094565/ https://www.ncbi.nlm.nih.gov/pubmed/33941197 http://dx.doi.org/10.1186/s12967-021-02859-6 |
Ejemplares similares
-
Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström’s Macroglobulinemia
por: Kaiser, Lisa Marie, et al.
Publicado: (2021) -
Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists
por: Sokkar, Pandian, et al.
Publicado: (2021) -
Development
of a New Class of CXCR4-Targeting Radioligands
Based on the Endogenous Antagonist EPI-X4 for Oncological Applications
por: Gaonkar, Raghuvir Haridas, et al.
Publicado: (2023) -
EPI-X4, a novel endogenous antagonist of CXCR4
por: Buske, Christian, et al.
Publicado: (2015) -
Development
of N-Terminally Modified Variants
of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability
por: Harms, Mirja, et al.
Publicado: (2023)